Related Experiment Videos

Lumbar myelography with amipaque

Spine
|March 1, 1978
PubMed

Insights

Amipaque (metrizamide) is a safe contrast medium for lumbar myelography, with rare serious side effects in 650 patients. Minor reactions occurred in 56%, but adhesive arachnoiditis was significantly less common.

Area of Science:

  • Radiology
  • Neurology

Background:

  • Lumbar myelography often causes side effects with water-soluble contrast media.
  • Amipaque (metrizamide) is a modern contrast agent for spinal imaging.

Purpose of the Study:

  • To evaluate the safety and efficacy of Amipaque in lumbar myelography.
  • To assess the incidence of adverse reactions and complications associated with Amipaque.

Main Methods:

  • A series of 650 consecutive lumbar myelographies using Amipaque.
  • Monitoring for early side effects, electroencephalogram (eeg) changes, and adhesive arachnoiditis.

Main Results:

  • No serious adverse effects were observed in 650 patients.
  • Minor adverse reactions occurred in 56% of patients.
  • Transient eeg changes in 14% and significantly lower incidence of adhesive arachnoiditis compared to other contrast media.

Conclusions:

  • Amipaque is a safe contrast medium for lumbar myelography with a low rate of serious adverse events.
  • It offers excellent visualization of the spinal subarachnoid space.
  • Amipaque is a valuable tool for spinal investigations, with a favorable safety profile regarding adhesive arachnoiditis.

Related Concept Videos